David Wainer at The Wall Street Journal reports on the recent trend of Chinese biotechs developing drugs faster and cheaper than their U.S. counterparts and global pharma sourcing close to 30% of their large deals from here. DealForma and Tim Opler at Stifel provided the data and context. Check out the article here.
